Pharmacogenomic Testing to Guide Treatment of Major Depressive Disorder: A Systematic Review

被引：0
|
作者：
Farah Khorassani
Mandy Jermain
Christine Cadiz
机构：
[1] University of California Irvine,Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences
[2] AbbVie Inc.,undefined
来源：
Current Treatment Options in Psychiatry | 2024年 / 11卷 / 2期
关键词：
Pharmacogenomics; Pharmacogenetics; Pharmacogenetic testing; Antidepressive agents; Depressive disorder; Depression;
D O I：
10.1007/s40501-024-00316-x
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：123 / 140
页数：17
相关论文
共 50 条
  • [1] Applicability of pharmacogenomic testing in the treatment of major depressive disorder
    Ramos, S.
    Sousa, D.
    Mendes, J.
    [J]. EUROPEAN PSYCHIATRY, 2020, 63 : S655 - S656
  • [2] Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder
    Mamdani, Firoza
    Berlim, Marcelo T.
    Beaulieu, Marie-Martine
    Turecki, Gustavo
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2014, 15 (02): : 135 - 144
  • [3] Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
    Hall-Flavin, Daniel K.
    Winner, Joel G.
    Allen, Josiah D.
    Carhart, Joseph M.
    Proctor, Brian
    Snyder, Karen A.
    Drews, Maureen S.
    Eisterhold, Linda L.
    Geske, Jennifer
    Mrazek, David A.
    [J]. PHARMACOGENETICS AND GENOMICS, 2013, 23 (10): : 535 - 548
  • [4] Lithium treatment for unipolar major depressive disorder: Systematic review
    Undurraga, Juan
    Sim, Kang
    Tondo, Leonardo
    Gorodischer, Ariel
    Azua, Emilio
    Tay, Kai Hong
    Tan, David
    Baldessarini, Ross J.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (02) : 167 - 176
  • [5] Botulinum Toxin for the Treatment of Major Depressive Disorder A Systematic Review
    Hawlik, A. E.
    Freudenmann, R. W.
    Pinkhardt, E. H.
    Schoenfeldt-Lecuona, C. J.
    Gahr, M.
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2014, 82 (02) : 93 - 99
  • [6] Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies
    Rosenblat, Joshua D.
    Lee, Yena
    McIntyre, Roger S.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2017, 78 (06) : 720 - 729
  • [7] Cost-Effectiveness of Combinatorial Pharmacogenomic Testing for Treatment-Resistant Major Depressive Disorder Patients
    Hornberger, John
    Li, Qianyi
    Quinn, Bruce
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (06): : E357 - +
  • [8] A systematic review of vortioxetine for major depressive disorder treatment in older people
    Byrne, A.
    Barber, R.
    Newby, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S222 - S222
  • [9] Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review
    Andrade, Pablo
    Noblesse, Lieke H. M.
    Temel, Yasin
    Ackermans, Linda
    Lim, Lee W.
    Steinbusch, Harry W. M.
    Visser-Vandewalle, Veerle
    [J]. ACTA NEUROCHIRURGICA, 2010, 152 (04) : 565 - 577
  • [10] Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review
    Pablo Andrade
    Lieke H. M. Noblesse
    Yasin Temel
    Linda Ackermans
    Lee W. Lim
    Harry W. M. Steinbusch
    Veerle Visser-Vandewalle
    [J]. Acta Neurochirurgica, 2010, 152 : 565 - 577
12345